Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

Abstract

Neutralizing antibody responses to coronaviruses mainly target the receptor-binding domain (RBD) of the trimeric spike. Here, we characterized polyclonal immunoglobulin Gs (IgGs) and Fabs from COVID-19 convalescent individuals for recognition of coronavirus spikes. Plasma IgGs differed in their focus on RBD epitopes, recognition of alpha- and beta-coronaviruses, and contributions of avidity to increased binding/neutralization of IgGs over Fabs. Using electron microscopy, we examined specificities of polyclonal plasma Fabs, revealing recognition of both S1 A and RBD epitopes on SARS-CoV-2 spike. Moreover, a 3.4 Å cryo-electron microscopy (cryo-EM) structure of a neutralizing monoclonal Fab-spike complex revealed an epitope that blocks ACE2 receptor binding. Modeling based on these structures suggested different potentials for inter-spike crosslinking by IgGs on viruses, and characterized IgGs would not be affected by identified SARS-CoV-2 spike mutations. Overall, our studies structurally define a recurrent anti-SARS-CoV-2 antibody class derived from VH3-53/VH3-66 and similarity to a SARS-CoV VH3-30 antibody, providing criteria for evaluating vaccine-elicited antibodies.

Cited by papers we hold 43

• How to Deal With Vaccine Breakthrough Infection With SARS-CoV-2 Variants · 2022
  Not checked
• Evolution of the SARS‐CoV‐2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission · 2022
  No notice
• Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination · 2022
  No notice
• Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models · 2022
  No notice
• Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection · 2021
  No notice
• Prolonged evolution of the human B cell response to SARS-CoV-2 infection · 2021
  No notice
• Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera · 2021
  No notice
• Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class · 2021
  Not checked
• A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants · 2021
  Not checked
• A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes · 2021
  Not checked
• Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice · 2021
  No notice
• Enhanced SARS-CoV-2 neutralization by dimeric IgA · 2021
  No notice
• SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion · 2021
  No notice
• Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant · 2021
  No notice
• mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection · 2021
  No notice
• Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines · 2021
  No notice
• Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants · 2021
  No notice
• Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies · 2021
  No notice
• A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies · 2021
  No notice
• Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape · 2021
  No notice

and 23 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.